Back

The efficacy of tafolecimab in lipoprotein(a) reductions in hypercholesterolaemic patients: a pooled analysis of three phase 3 trials

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (1) - Dyslipidaemias: current strategies and innovations Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Ms Hua Shen

Beijing Anzhen Hospital, Beijing (China)

9 More presentations in this session

Presentation thumbnail
Discussant - Dyslipidaemias: current strategies and innovations
Presentation thumbnail
The efficacy and safety of low-intensity statins for high bleeding risk patients after PCI in Asian populations
Doctor Z. Zhang (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Statin users have lower fatty acid oxidative metabolisms in muscle mitochondria and have a higher content of long-chain and medium-chain acylcarnitines in muscles.
Doctor E. Bolsteina (Riga, LV)
Abstract Slides
Presentation thumbnail
Efficacy and metabolic impact of combination therapy vs. high-intensity statin monotherapy: an exploratory analysis of the Save SAMS Trial
Professor S. Hong (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
VICTORION-Mono China: efficacy and safety of inclisiran as monotherapy in Chinese adults with low or moderate ASCVD risk and elevated LDL-C
Doctor X. Liu (CH)
Abstract

Access the full session

Session thumbnail
New perspectives in cardiology (1) - Dyslipidaemias: current strategies and innovations

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Effects of lipid-lowering therapies on lipoprotein(a) levels in patients with dyslipidemia: a systematic review and network meta-analysis of 64 randomised controlled trials
thumbnail
Congress Presentation
Lipoprotein (a) and lipidemic parameters in PCSK-9 inhibitor patients. Experience from a specialized centre in Greece.
thumbnail
Congress Presentation
Impact of Lp(a) on lipid control in patients with acute coronary syndrome

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources